Park Avenue Securities LLC Buys 4,177 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Park Avenue Securities LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 15.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,828 shares of the company’s stock after purchasing an additional 4,177 shares during the period. Park Avenue Securities LLC’s holdings in Takeda Pharmaceutical were worth $473,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Blair William & Co. IL lifted its holdings in Takeda Pharmaceutical by 8.1% during the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company’s stock valued at $162,000 after buying an additional 913 shares in the last quarter. Vise Technologies Inc. lifted its holdings in shares of Takeda Pharmaceutical by 3.1% during the 4th quarter. Vise Technologies Inc. now owns 34,635 shares of the company’s stock valued at $459,000 after purchasing an additional 1,026 shares during the last quarter. Sage Rhino Capital LLC boosted its holdings in Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company’s stock worth $157,000 after acquiring an additional 1,538 shares in the last quarter. Vident Advisory LLC grew its position in Takeda Pharmaceutical by 13.5% during the 4th quarter. Vident Advisory LLC now owns 13,606 shares of the company’s stock worth $180,000 after purchasing an additional 1,616 shares during the last quarter. Finally, OLD Mission Capital LLC increased its position in shares of Takeda Pharmaceutical by 13.7% in the 4th quarter. OLD Mission Capital LLC now owns 13,977 shares of the company’s stock valued at $185,000 after acquiring an additional 1,687 shares during the period. 9.17% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $15.20 on Friday. The company’s fifty day moving average price is $14.71 and its 200 day moving average price is $14.16. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43. The company has a market capitalization of $48.37 billion, a PE ratio of 38.00, a price-to-earnings-growth ratio of 0.24 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to analysts’ expectations of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.